Iodide symporter gene expression in human thyroid tumors
Iodide symporter gene expression in human thyroid tumors
复制标题
DOI：
10.1210/jc.83.7.2493
复制
发表时间：
1998-07-01
影响因子：
5.8
通讯作者：
Filetti, S
中科院分区：
文献类型：
--
作者：
Arturi, F;Russo, D;Filetti, S
采用RT-PCR方法检测了26例原发性甲状腺癌（乳头状癌19例，滤泡状癌5例，间变性癌2例）中Na/+I-同向转运体（NIS）基因的表达。还研究了15个滤泡性腺瘤（11个“冷“腺瘤和4个“热”腺瘤）。19例甲状腺乳头状癌中5例不表达NIS信使核糖核酸（mRNA）。除1例滤泡癌外，其他所有滤泡癌均完全检测到NIS转录物。在间变性组织中，只有1例几乎未检测到NIS mRNA。除1例外，所有滤泡性甲状腺腺瘤均表达NIS基因。与此相反，所有的肿瘤研究，不包括间变性组织型完全表达甲状腺球蛋白和甲状腺过氧化物酶mRNA转录。在2例患者中，通过斑点杂交分析发现，与正常和原发性甲状腺肿瘤组织相比，转移灶中NIS mRNA的表达较低（3- 5倍）。8例分化型甲状腺癌患者中有4例因治疗后I-131全身扫描阴性而出现转移，显示其原发癌中缺乏NIS基因表达。这种缺陷，至少在这些情况下，是原发癌细胞的体细胞和内在病变，而不是由于转移组织中的去分化过程。因此，早期检测原发癌中NIS基因表达的缺失可能为分化型甲状腺癌患者的治疗提供有用的信息。
Expression of the Na/+I- symporter (NIS) gene was investigated by RT-PCR in a selected series of 26 primary thyroid carcinomas (19 papillary, 5 follicular, and 2 anaplastic). Fifteen follicular adenomas (11 "cold " and 4 "hot" adenomas) were also studied. Five of 19 papillary thyroid cancer did not express NIS messenger ribonucleic acid (mRNA). In all but 1 follicular cancer, NIS transcript was fully detected. In anaplastic tissue, NIS mRNA was only barely detected in 1 case. All of the follicular thyroid adenomas except 1 expressed the NIS gene. In contrast, all tumors studied excluding the anaplastic histotype fully expressed thyroglobulin and thyroid peroxidase mRNA transcripts. In 2 patients, a lower expression (3- to 5-fold) of NIS mRNA was found in metastasis by dot blot analysis compared with those in both normal and primary neoplastic thyroid tissue. Four of 8 differentiated thyroid cancer patients selected for the presence of metastases with negative posttherapy I-131 total body scan showed the lack of NIS gene expression in their primary cancer. This defect, at least in these cases, is a somatic and intrinsic lesion of the primary cancer cells and is not due to a dedifferentiation process in the metastatic tissue. The early detection of the loss of NIS gene expression in the primary cancer, therefore, may provide useful information for the management of differentiated thyroid cancer patients.